"I’ve had the great fortune of spending my career helping to define and then apply human genomics to improve health. Genomic Health is unique in its singular focus on improving the lives of cancer patients by applying genomic insights to critical decisions in a patient’s journey. It’s a privilege to lead our new product research and development efforts on liquid biopsy. We are developing exciting new technologies for future tests while maintaining our relentless focus on patient impact with today’s Oncotype DX® tests. It’s an honor to be part of such a smart, dedicated and collaborative team."
Ellen Beasley has over 20 years of product development and program management experience in biotechnology and genomics sciences. She brings a record of successful integration and application of bioinformatics, genetics and genomics platforms to advance and accelerate life sciences instrument, diagnostics and therapeutics product discovery and development. Ellen started her career in human genomics at the Stanford Human Genome Center and lead the team developing physical maps of the human genome. She then moved to Celera Genomics and participated in the genome sequencing and gene discovery efforts for the human genome. After the completion of the human genome, Ellen managed various discovery efforts to apply the human genome, including drug target discovery efforts, investigation of the genetic basis of autoimmune disease and companion diagnostic partnership development. Ellen then moved to Perlegen Sciences where she was Senior Vice President of R&D Operations, managing companion diagnostic programs and building the CLIA lab for commercialization of a breast cancer risk assay. In 2009, Ellen joined Life Technologies and was Vice President of Biological Information Systems, leading a team to develop methods and software tools to exploit the data from next generation sequencers. Since joining Genomic Health in 2013, Ellen has focused on the application of next generation technologies, including sequencing and liquid-based biopsy, to discover and develop Genomic Health's next generation of products to serve patients living with cancer. In 2017, Ellen was recognized for her leadership in biotechnology and named one of the Most Influential Women in Business by San Francisco Business Times. Ellen received a Bachelor of Science (honors) in Biology from Trinity College (Hartford, CT) and a Ph.D. in Molecular Genetics and Cell Biology from The University of Chicago, she completed post-doctoral training at the Biozentrum of the University of Basel in Switzerland and Stanford University. Ellen is an inventor on approximately 185 patents.
Oncotype DX My Colon Cancer Coach